Search results
What Is Immunophenotyping?
Healthline· 5 days agoImmunophenotyping helps doctors diagnose and classify specific blood cell cancers, like leukemia and lymphoma, as well as other diseases....
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA)...
WTRF Wheeling· 5 days agoMoleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses ...
Brookfield cancer patient gets ‘a second chance on life’ with stem cells from a Canadian athlete
The News-Times· 7 days agoSubmission of a sample to a national donor program sparked an unexpected connection between a...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 5 days agoMoleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress PR Newswire HOUSTON, May 16, 2024 HOUSTON, May 16, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or
Former patients reunite as professionals at UPMC Children's Hospital of Pittsburgh
Pittsburgh Tribune-Review· 4 days agoDr. Matt Kocher was setting up an operating room during his anesthesia fellowship at UPMC Children’s...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 4 days agoMP0533: Phase 1 trial continues to demonstrate acceptable safety and antitumor activity up to cohort 6, dosing in cohort 7 ongoing, additional dose escalation cohorts being preparedRadio-DARPin Therapy (RDT): Lead DLL3 candidate advancing into
Metformin Unveils Its Hidden Talent in Cancer Prevention
SciTechDaily· 3 days agoA study suggests that metformin, typically used for type 2 diabetes, may reduce the risk of myeloproliferative neoplasms (MPN) by leveraging its anti-inflammatory effects to prevent excessive ...
HC Wainwright Cuts Cullinan Oncology (NASDAQ:CGEM) Price Target to $28.00
ETF DAILY NEWS· 2 days agoCullinan Oncology (NASDAQ:CGEM – Free Report) had its target price decreased by HC Wainwright from $29.00 to $28.00 in a report released on Thursday morning, Benzinga reports. HC Wainwright ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 6 days agoVincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC) The National Institutes of Health
Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by Analysts at StockNews.com
ETF DAILY NEWS· 2 days agoStockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Free Report) in a report issued on Saturday. The firm issued a sell rating on the stock. Ayala Pharmaceuticals ...
